The DNA-dependent protein kinase (DNA-PK) complex is composed of a catalytic (DNA-PK cs ), and a regulatory subunit (Ku70/Ku86 heterodimer). The expression and function of DNA-PK subunits was investigated in puri®ed blood lymphocytes obtained from patients with chronic lymphocytic leukemia (CLL) either refractory to chemotherapy or untreated. Variations in DNA-PK activity were found amongst CLL samples by comparison to human cell lines. It was noticeable that the low DNA-PK activity was associated with samples from untreated patients that exhibited a sensitivity phenotype, determined in vitro, to the radiomimetic agent neocarcinostatin by comparison to samples from refractory patients. The regulation in DNA-PK activity was associated with Ku heterodimer expression while DNA-PK cs was unaected. Moreover, the presence of an altered form of the Ku86 subunit was identi®ed in samples with low DNA-PK activity. These results suggest a regulation process of the DNA-PK activity in fresh human cells.
Introduction
The DNA-dependent protein kinase (DNA-PK) plays an important role in the repair of DNA double-strand breaks (DSB) and in the V(D)J recombination (Finnie et al., 1996; Jeggo et al., 1995; Weaver, 1995) . DNA-PK is a nuclear protein serine/threonine kinase that comprises a large catalytic subunit (460 kDa), DNA-PK cs , and a DNA binding sub-unit, the Ku autoantigen. The Ku autoantigen, a heterodimer of the Ku 70 and Ku 86 proteins, binds to DNA double strand ends and other discontinuities in the DNA (Blier et al., 1993; Falzon et al., 1993; Minori and Hardin, 1986) and recruits the catalytic subunit of the complex (Gottlieb and Jackson, 1993) . The active DNA-PK complex then acquires the capacity, at least in vitro, to phosphorylate many DNA-bound proteins in the vicinity (Anderson et al., 1994) . Several DNA-binding protein have been shown to be substrates for DNA-PK cs mediated phosphorylation in vitro, including the transcription factor Sp1, c-jun, c-fos and Oct-1, the tumor suppressor gene p53 and the carboxyl-terminal domain of RNA polymerase II (Anderson et al., 1994) .
Despite many studies with established cell lines little is known about DNA-PK activity and its regulation in fresh human cells and tissues. No signi®cant variations in DNA-PK activity measured in extracts from various human cell lines were observed leading to the idea that DNA-PK expression was constitutively expressed in cells. In a ®rst step to explore this issue, we have chosen to study DNA-PK activity in lymphocytes obtained from patients with chronic lymphocytic leukemia (CLL), a disease state characterized by the proliferation of abnormal, developmentally immature B cells or, exceptionally T lymphocytes (Kipps, 1995) . CLL seemed to be an interesting tumor model for this study since blood samples usually provide large quantities of cells that can be easily puri®ed leading to a pure tumoral cell population. In the present study, we have examined the expression and function of DNA-PK subunits in lymphocytes from CLL patients in order to characterize DNA-PK activity in fresh leukemic cells.
Results

DNA-PK activity in lymphocytes from CLL patients
The DNA-PK activity was determined by using a highly sensitive assay (Finnie et al., 1995) in whole cell extracts from 9 CLL lymphocyte samples. Extracts from AHH1, MRC5 and HeLa cells were used to compare the DNA-PK activity measured in cell lines versus fresh cells. DNA-PK activity was present in all CLL extracts analysed, but its level varied between samples (Figure 1) . In ®ve samples, the DNA-PK activity appears similar to that observed in the three cell line extracts (representative of the level of activity observed in a panel of cell lines of human origin, data not shown). In contrast, in four samples, the level of DNA-PK activity was signi®cantly lowered to about 2.6-fold (3107+1033 versus 8458+1180 c.p.m. incorporated in the substrate peptide, respectively, P50.001).
Sensitivity of CLL lymphocytes to neocarcinostatin and alkylating agents
In order to examine a putative relation between variations in DNA-PK activity and in vitro cell sensitivity, survival curves were determined by the MTT assay, already validated with these cells (Bramson et al., 1995a) . Four samples exhibited a sensitive phenotype to the radiomimetic agent neocarcinostatin (about ®vefold) by comparison with the ®ve other samples (Figure 2 ). Based upon these results, we de®ned two groups, group I (samples 1 ± 5) and group II (samples 6 ± 9) resistant and sensitive to neocarcinostatin, respectively. The mean IC 50 to neocarcinostatin was 56.8+11.7 nM versus 9.8+2.3 nM for group I and group II, respectively (see Table 1 ). Interestingly, samples in group I were obtained from refractory patients, while samples in group II were from untreated patients. Despite the small number of samples in each group and intra-group variation, sensitivity to neocarcinostatin of group II samples was in accordance to low DNA-PK activity, by comparison with group I. In addition, as shown in Table 1 , lymphocytes from the ®ve treated-resistant patients (group I) were resistant to chlorambucil in vitro (about fourfold) by comparison with those from the four untreated patients (group II), which illustrates an accordance between in vitro cell sensitivity and clinical data, although it is unknown whether the group II patients will be clinically responsive to chlorambucil. This is not surprising since clinical studies have established that 60 to 80% of the patients will respond to chlorambucil administered as ®rst line therapy (Kipps, 1995) . To further con®rm that in our series resistance to chlorambucil is associated with resistance to other bifunctional alkylating agents as previously described (Bramson et al., 1995a ) the sensitivity of CLL lymphocytes to mechlorethamine was tested. The group I samples were found to be 3.4-fold more resistant to mechlorethamine than those from group II ( Table 1) .
Basis of the dierence in DNA-PK activity in lymphocytes from CLL patients
Variations in DNA-PK activity might stem from various mechanisms among them dierential Ku/ DNA binding and DNA-PK cs expression. First, it was shown that the DNA-PK cs (460 000 m.w) polypeptide was detected in all extracts at almost similar amounts between the dierent samples ( Figure 3a) . Second, the DNA-end binding (DEB) activity of Ku 70/Ku 86 was determined by electrophoretic mobility shift assays (EMSA) since Ku/DNA binding represents the early limiting step for the formation of an active DNA-PK complex. The major Ku/DNA complex was present in cell extracts from AHH1 and HeLa cell lines (complex A) (Figure 3b ). Additional slower migrating complexes (A' and A'') were observed that appeared to depend upon Ku concentration and are likely to correspond to the binding of multiple Ku heterodimers to the same DNA-probe ( deVries et al., 1989; Yaneva and Jhiang, 1991) . When the CLL extracts were considered the results obtained consistently showed two features ( Figure 3b ): (i) the Ku DEB activity was higher in group I than in group II when Figure 1 DNA-PK activity in CLL lymphocytes. Extracts (50 mg) were analysed by the DNA-PK pull-down assay in the presence of wild-type or mutated peptide as indicated in Material and methods. The established cell lines corresponded to AHH1, HeLa and SKOV3 cells. Samples from nine patients were tested (1 ± 9). Each value was the mean of at least two independent cell extracts per sample Figure 2 Survival to neocarcinostatin treatment. Survival was determined as reported in the Materials and methods section by the MTT procedure. Lymphocytes from the nine patients (1 ± 9) were tested. Each value was the mean of at least two independent experiments per sample the formation of complex A and of the corresponding slower-migrating complex (A' and A'' were considered; (ii) within group II samples, in addition to the major complex (A, A', A''), a new complex (B) with faster electrophoretic mobility was present. This latter result suggests that an altered form of the Ku heterodimer may be expressed in CLL extracts obtained from untreated patients.
Expression and function of DNA-PK complex in CLL nuclear extracts
Another way of regulating DNA-PK activity in CLL might be a dierential distribution of the proteins involved in the complex. We examined the nuclear and cytoplasmic compartments of two samples: one from group I where the usual pattern of Ku DEB activity is observed (sample no 1) and one from group II where the pattern of Ku DEB activity revealed the presence of the altered heterodimer (sample no 6). First, nuclear (NE) and post-nuclear (PNE) extract fractions were analysed separately by immunoblotting for p62 expression, a component of the TFIIH basal transcription factor (Svejstrup et al., 1996) , in order to validate the quality of the sub-cellular fractionnement. As expected, its expression was restricted to nuclei in both samples (Figure 4 ). Concerning DNA-PK protein complex expression, the following results were found ( Figure 4 ): (i) the DNA-PK cs was predominantly present in the nuclear fraction with little or none in the cytoplasmic fraction; (ii) the expression of Ku 70 and Ku 86 proteins was observed in both nuclear and cytoplasmic extracts, although predominantly in the nuclear fraction of the two samples; (iii) the level of the nuclear expression of full-length Ku 70 and Ku 86 proteins was higher in the extracts from sample 1 than from sample 6; (iv) in addition to the full-length Ku 86 protein, a second immunoreactive band present as a doublet (at approximately 69 and 71 kDa) was detected in the nuclear extract obtained from the untreated patient (no 6) whereas Ku 70 protein was detected as a unique band in both samples. This variant form of the Ku 86 protein was also detected by Western blot in two other extracts obtained from untreated patients (no 7 and 9) (data not shown). Finally, in EMSA experiments complex B found in sample no 6 was only detected after the fractionation procedure in the nuclear extract (data not shown). Thus, these experiments suggest that the altered form of the heterodimer indeed corresponded to the expression of a variant form of the Ku 86 protein as previously described in HL60 cell line (Han et al., 1996) and that the Ku-86 variant is localized in the nucleus of CLL lymphocytes.
Discussion
The DNA-dependent protein kinase (DNA-PK) complex, composed of DNA-PK cs and Ku subunits, plays a Finnie et al., 1996) and unpublished results) leading to the idea that the kinase activity was constitutively expressed. We showed here, for the ®rst time, that DNA-PK activity could be measured in primary human tumour cells and more importantly that its level of activity varied amongst CLL samples. Interestingly, even in advanced disease, cell cycle analysis consistently showed that most malignant CLL cells are in G0/G1 phase and very few in S phase (Orfao et al., 1992) . Thus, DNA-PK activity appears to be present even in non-cycling primary human tumour cells. In CLL cells, changes in DNA-PK activity appeared to be regulated through a variation in the Ku heterodimer DEB activity but also potentially through the expression of an altered form of the heterodimer (detected in all the four samples with low DNA-PK activity, Figure 3b ), due to the appearence of a variant form of the Ku 86 protein, that could negatively regulate the DNA-PK activity in these cells. Recently, the expression of an altered form of the Ku heterodimer with faster electrophoretic mobility as detected by EMSA has been reported in the HL60 cell line (Han et al., 1996) . This altered form of the Ku heterodimer, that contained Ku 70 and a variant Ku 86 protein, was unable to recruit DNA-PK cs leading to a loss of DNA-PK activity in these cells. The variant form of the Ku 86 protein detected in the CLL samples presents similarities with the protein detected in the HL 60 cell line. In both studies, the mAb S10B1 (which recognizes an epitope de®ned by aa 8 ± 221 on the N terminus of Ku 86) detected a doublet consisting of two lower forms of the Ku 86 protein with apparent molecular weight of 69 and 71 kDa. Thus, our results show that the expression of this variant Ku 86 is observed in primary human cells and is likely to be an important mechanism of regulation of DNA-PK activity in vivo. Preliminary experiments performed in our laboratory show that the altered form Ku heterodimer is also present in normal circulating lymphocytes (C Muller et al., unpublished results) . Finally, immunoblotting revealed the presence of the two subunits of the Ku heterodimer in the nuclei and cytoplasm of CLL cell extracts. In contrast, it has been previously reported that, in normal human lymphocytes, Ku proteins are strictly con®ned to the nucleus (Reeves, 1987; Yaneva and Jhiang, 1991) . Thus, a dierent pattern of cellular distribution may be associated with the malignant phenotype of the cells and these results may suggest that dierences occur between malignant and normal B-lymphocytes with regards to the regulation of Ku expression and function.
Taking into account the origin of the samples tested, the decreased kinase activity was observed only in lymphocytes from untreated patients by comparison with those from treated-refractory patients. In the light of the clinical status of the disease, basically the lymphocytosis, alykylating agents such as chlorambucil are used in ®rst treatment. These drugs covalently bind to DNA and induce the formation of various adducts among them inter-strand cross-links. Previous studies have established that the development of chlorambucil resistance in CLL is associated with enhanced repair of DNA crosslinks which may involve a recombination dependent pathway (Bramson et al., 1995b; Panasci et al., 1988) . Consequently, DNA-PK activity is likely to play a role in this phenotype. Indeed, we have shown that the increase in DNA-PK activity resulted in increased resistance to neocarcinostatin and chlorambucil, suggesting that the levels of DNA-PK activity is implicated in the regulation of DNA DSBs repair in these cells. However, further studies will be needed with a large number of samples directly to correlate DNA-PK activity, enhanced crosslinks removal and drug resistance in CLL.
In conclusion, this ®rst study on DNA-PK activity in primary human tumor cells opens promising perspectives. First, our study suggest that changes in DNA-PK may play an important role in regulating tumor treatment response to radiotherapy and DNA cross-linking agents. Secondly, the mechanism of regulation of this activity in primary tumor cells is likely to involve the relative expression a variant form of the Ku 86.
Materials and methods
Patient characteristics
Nine patients (Service d'HeÂ matologie, Hopital Purpan, Toulouse, France) were enrolled in the study. Table 2 summarizes their main clinical features. All patients had Bcell derived CLL. Patients were either untreated (no 6 ± 9) or treated-resistant (no 1 ± 5). Patients with resistant B-CLL had received 4 ± 6 mg of chlorambucil daily for 6 months or more. All the patients with resistant disease had previously responded to chlorambucil and were progressive at the time at the analysis.
Peripheral blood lymphocytes and transformed cell lines.
Blood (50 ml) from patients who gave informed consent was collected into heparinized tubes. Monuclear cell suspensions were obtained after Hypaque-Ficoll (MSL, Eurobio, France) gradient centrifugation as described previously (Barret et al., 1996) . The monocytes were removed by adherence. After centrifugation of the nonadherent lymphocytes, cell extracts were immediately prepared from the pellets. The AHH1, HeLa and MRC5 cell lines have been described previously (Barret et al., 1996) .
Cytotoxicity assay
B-CLL lymphocytes, to a ®nal concentration of 1.5610 6 to 3610 6 cells/mL, were seeded into 96-well microculture dishes in aliquots of 100 ml. The lymphocytes were then exposed to increasing concentrations of neocarcinostatin (gift from Dr V Favaudon, Institut Curie, Orsay, France), chlorambucil or mechlorethamine (Sigma, France) for 48 h at 378C under 5% CO 2 . Five replicates of each drug concentration were performed. After 48 h, growth inhibition was evaluated by the MTT colorimetric method as described previously (Muller et al., 1994) .
Cell extracts
Whole cell extracts (WCE) were prepared as described previously (Finnie et al., 1995) . Nuclear (NE) and postnuclear (PNE) cell extracts were prepared as follows: cells were washed twice in phosphate-buered saline, and suspended in 0.5 to 2 mL of ice-cold hypotonic buer A (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl 2 ) in the presence of proteinase inhibitors as described above for whole cell extracts. Cells were broken in a Dounce homogenizer and the suspension centrifuged for 2 min at 5000 r.p.m. at 48C. The PNE was carefully removed from the nuclear pellet, frozen in liquid nitrogen and stored at 7708C. The pellet was suspended in buer A and the lysate was layered on the top of 5 mL ice-cold sucrose buer (buer A with 30% sucrose) and puri®ed nuclei were obtained at the bottom of the tubes after centrifugation at 2000 r.p.m. at 48C for 5 min. The pellet was resuspended in lysis buer A, and the nuclei were puri®ed by centrifugation through sucrose medium twice. Nuclei were then resuspended in extraction buer and processed as described above for whole cell extracts to obtain the NE.
DNA-dependent protein kinase activity DNA-PK`pulldown' kinase assay was performed as previously described (Finnie et al., 1995) . Each sample was assayed in the presence of the peptide EPPLSQEA-FADLLKK, part of the p53 protein that is phosphorylated by DNA-PK and the mutated peptide EPPLSEQA-FADLLKK as a negative control. Radioactivity associated with the mutated peptide was in the range 6 ± 10% of that with the substrate peptide. DNA-PK activity is expressed as the dierence of radioactivity incorporated by the substrate minus the mutated peptide for a given extract.
Ku DNA-end binding activity
The band shift assay was performed as described previously (Zhang and Yaneva, 1992) . The 123 bp linear probe used is obtained by AvaI digestion of a 123 bp DNA ladder, followed by puri®cation of 123 bp-monomers.
Western blot
Proteins were subjected to electrophoresis on a 8% SDSpolyacrylamide gel, then electroblotted onto a nitrocellullose ®lter (Bio-Rad Trans-Blot). Western blots experiments were performed as described previously (Muller et al., 1994) . The antibodies used were as follows: the polyclonal antibody directed against Ku 70 protein (provided by Dr Falaschi, UNIDO, Trieste, Italy) (Tuteja et al., 1994 ) was used at a 1 : 2500 dilution (secondary antibody mouse antirabbit at a 1 : 2500 dilution); the puri®ed monoclonal antibodies directed against Ku 86 (mAb S10B1, Interchim, France) (Wang et al., 1993) , DNA-PK cs (mAb 18-2 provided by Dr T Carter, St-John's University, New York, USA) (Carter et al., 1990) , p62 (a subunit of the transcription factor TFIIH; provided by Dr JM Egly, IGBM, Strasbourg, France) were used at 1 : 1000, 1 : 5000 and 1 : 5000, respectively (secondary antibody goat antimouse at a 1 : 2500, 1 : 5000 and 1 : 5000 dilution, respectively).
